CPC G01N 33/5061 (2013.01) [C12N 5/0658 (2013.01); C12N 5/0696 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2503/02 (2013.01); C12N 2506/1307 (2013.01); C12N 2506/45 (2013.01)] | 13 Claims |
1. A method of screening for candidate therapeutic agents, comprising: obtaining fibroblasts from a subject diagnosed as having a muscular dystrophy and generating induced pluripotent stem cells (iPSCs); culturing the iPSCs; differentiating the iPSCs to generate myoblasts; contacting the myoblasts with a candidate therapeutic agent; culturing the myoblasts with a detectably labeled anti-myosin heavy chain antibody; and, imaging and analyzing the myoblasts generated from the iPSCs of the subject diagnosed with muscular dystrophy as compared to myoblasts generated from a healthy subject's iPSCs, wherein the analysis comprises measuring average length of myoblasts and expression of myosin heavy chain (MyHC) polypeptides as compared to positive and negative controls; and wherein the average length of myoblasts is determined by: cell average length+0.3*MyHC (myosin heavy chain); thereby, screening for the candidate therapeutic agent.
|